Cyclacel Pharmaceuticals logo
Cyclacel’s CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers
August 02, 2016 07:00 ET | Cyclacel
- Data support CYC065 as potential treatment for chemotherapy-resistant, CCNE1-amplified, uterine serous carcinoma (USC); 90% of tumor samples overexpressed cyclin E1 (CCNE1) - BERKELEY HEIGHTS,...
Cyclacel Pharmaceuticals logo
Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
April 18, 2016 09:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., April 18, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data...